(VIANEWS) – Monolithic Power Systems (MPWR), Camtek Ltd. (CAMT), Chesapeake Utilities Corporation (CPK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Monolithic Power Systems (MPWR)
32.7% sales growth and 20.37% return on equity
Monolithic Power Systems, Inc. engages in the design, development, marketing, and sale of semiconductor-based power electronics solutions for the storage and computing, automotive, enterprise data, consumer, communications, and industrial markets. The company provides direct current (DC) to DC integrated circuits (ICs) that are used to convert and control voltages of various electronic systems, such as cloud-based CPU servers, server artificial intelligence applications, storage applications, commercial notebooks, digital cockpit, power sources, home appliances, 4G and 5G infrastructure, and satellite communications applications. It offers lighting control ICs for backlighting that are used in systems, which provide the light source for LCD panels in computers and notebooks, monitors, car navigation systems, and televisions, as well as for general illumination products. The company sells its products through third-party distributors, value-added resellers, directly to original equipment manufacturers, original design manufacturers, electronic manufacturing service providers, and other end customers. It serves China, Taiwan, South Korea, Europe, Japan, Southeast Asia, the United States, and internationally. Monolithic Power Systems, Inc. was incorporated in 1997 and is headquartered in Kirkland, Washington.
Earnings Per Share
As for profitability, Monolithic Power Systems has a trailing twelve months EPS of $8.76.
PE Ratio
Monolithic Power Systems has a trailing twelve months price to earnings ratio of 75.14. Meaning, the purchaser of the share is investing $75.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.37%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 28, 2024, the estimated forward annual dividend rate is 5 and the estimated forward annual dividend yield is 0.53%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15%, now sitting on 1.89B for the twelve trailing months.
Yearly Top and Bottom Value
Monolithic Power Systems’s stock is valued at $658.23 at 01:22 EST, way below its 52-week high of $956.63 and way above its 52-week low of $392.10.
Moving Average
Monolithic Power Systems’s worth is way below its 50-day moving average of $839.41 and under its 200-day moving average of $701.23.
2. Camtek Ltd. (CAMT)
27.4% sales growth and 21.2% return on equity
Camtek Ltd., together with its subsidiaries, develops, manufactures, and sells inspection and metrology equipment for the advanced interconnect packaging, memory, complementary metal oxide semiconductor image sensors, micro-electro mechanical systems, radio frequency, and other segments of the semiconductor industry. It provides inspection and metrology systems, including Eagle-i, a system that delivers 2D inspection and metrology capabilities; Eagle-AP, which addresses the advanced packaging market using software and hardware technologies that deliver superior 2D and 3D inspection and metrology capabilities on the same platform; and Golden Eagle, a panel inspection and metrology system to support fanout wafer level packaging applications. The company sells its products in the Asia Pacific, the United States, and Europe. Camtek Ltd. was incorporated in 1987 and is headquartered in Migdal HaEmek, Israel.
Earnings Per Share
As for profitability, Camtek Ltd. has a trailing twelve months EPS of $1.97.
PE Ratio
Camtek Ltd. has a trailing twelve months price to earnings ratio of 47.68. Meaning, the purchaser of the share is investing $47.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.2%.
Sales Growth
Camtek Ltd.’s sales growth is 35.1% for the ongoing quarter and 27.4% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 3, 2024, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 1.43%.
Volume
Today’s last reported volume for Camtek Ltd. is 86377 which is 87.32% below its average volume of 681298.
Moving Average
Camtek Ltd.’s value is way under its 50-day moving average of $112.17 and way above its 200-day moving average of $84.71.
3. Chesapeake Utilities Corporation (CPK)
24.8% sales growth and 9.21% return on equity
Chesapeake Utilities Corporation operates as an energy delivery company. The Regulated Energy segment engages in the natural gas distribution operations in central and southern Delaware, Maryland's eastern shore, and Florida; regulated natural gas transmission in the Delmarva Peninsula and Florida; and regulated electric distribution in northeast and northwest Florida. The Unregulated Energy segment engages in the propane operations in the Mid-Atlantic region and Florida; unregulated natural gas transmission/supply operation in central and eastern Ohio; generation of electricity and steam; and provision of compressed natural gas, liquefied natural gas, and renewable natural gas transportation and pipeline solutions primarily to utilities and pipelines in the eastern United States. This segment also provides other unregulated energy services, such as energy-related merchandise sales; heating, ventilation, and air conditioning services; and plumbing and electrical services. The company was founded in 1859 and is headquartered in Dover, Delaware.
Earnings Per Share
As for profitability, Chesapeake Utilities Corporation has a trailing twelve months EPS of $4.68.
PE Ratio
Chesapeake Utilities Corporation has a trailing twelve months price to earnings ratio of 24.97. Meaning, the purchaser of the share is investing $24.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.21%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Sep 16, 2024, the estimated forward annual dividend rate is 2.56 and the estimated forward annual dividend yield is 2.19%.
Volume
Today’s last reported volume for Chesapeake Utilities Corporation is 79385 which is 30.98% below its average volume of 115033.
Yearly Top and Bottom Value
Chesapeake Utilities Corporation’s stock is valued at $116.88 at 01:22 EST, under its 52-week high of $120.84 and way above its 52-week low of $83.80.
4. Spotify (SPOT)
21.8% sales growth and 14.76% return on equity
Earnings Per Share
As for profitability, Spotify has a trailing twelve months EPS of $-2.97.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.76%.
Moving Average
Spotify’s value is below its 50-day moving average of $321.30 and way above its 200-day moving average of $263.82.
Previous days news about Spotify(SPOT)
- The zacks analyst blog highlights Taiwan Semiconductor, spotify, seagate technology and eaton. According to Zacks on Friday, 23 August, "(TSM Quick QuoteTSM – Free Report) , Spotify Technology S.A. (SPOT Quick QuoteSPOT – Free Report) , Seagate Technology Holdings plc (STX Quick QuoteSTX – Free Report) and Eaton Corp. plc (ETN Quick QuoteETN – Free Report) .", "Four such stocks with strong earnings estimate revisions are Taiwan Semiconductor Manufacturing Co. Ltd., Spotify Technology S.A., Seagate Technology Holdings plc and Eaton Corp. plc."
5. CBIZ (CBZ)
7.7% sales growth and 14.11% return on equity
CBIZ, Inc. provides financial, insurance, and advisory services in the United States and Canada. The company operates through three segments: Financial Services, Benefits and Insurance Services, and National Practices. The Financial Services segment offers accounting and tax, government healthcare consulting, financial advisory, valuation, and risk and advisory services. The Benefits and Insurance Services provides group health benefits consulting, payroll, property and casualty, and retirement plan services. The National Practices segment offers managed networking and hardware, and health care consulting services. It primarily serves small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises. The company was founded in 1987 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, CBIZ has a trailing twelve months EPS of $2.33.
PE Ratio
CBIZ has a trailing twelve months price to earnings ratio of 30.91. Meaning, the purchaser of the share is investing $30.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.11%.
Sales Growth
CBIZ’s sales growth is 7.2% for the current quarter and 7.7% for the next.
Volume
Today’s last reported volume for CBIZ is 291462 which is 16.94% below its average volume of 350945.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 13.4% and 38.5%, respectively.
6. Kamada Ltd. (KMDA)
7.2% sales growth and 5.9% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.23.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 23.17. Meaning, the purchaser of the share is investing $23.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.9%, now sitting on 149.54M for the twelve trailing months.
Sales Growth
Kamada Ltd.’s sales growth is 6% for the ongoing quarter and 7.2% for the next.
